hronic pain syndromes, described throughout guidelines. men pain post inguinal hernia repair, limited evidence case series showing neurectomy damaged nerves lead symptomatic benefit . scrotal pain post vasectomy, affected men may find reversal vasectomy cure symptoms especially patency achieved . prospective rct, pulsed radio-frequency ilioinguinal genitofemoral nerves associated high rates symptomatic improvement (80%) follow limited three months . evidence epididymectomy poor considered, less likely provide benefit epididymis normal sonographic appearance . chronic gynaecological pain difficult compare wide variation drugs efficacy safety perspective diverse uses/indications. gynaecological patients chronic pelvic pain unrelated well-defined conditions, often difficult determine therapeutic pathway multidisciplinary chronic abdomino-pelvic pain management plan. cochrane review suggests may evidence (moderate) supporting use progestogens . though efficacious, physicians need knowledgeable progestogenic side effects (e.g., weight gain, bloatedness - common adverse effects) stop patients accepting medication. gonadotropin-releasing hormone (gnrh), goserelin, also thought help pain. however, compared progestogens, efficacy remains limited. quality evidence generally low drawn single studies . gonadotropin-releasing hormone hand binds specific receptors pituitary gonadotrophs, leading desensitisation consequently suppressed gonadotropin secretion. contrast, gnrh antagonists compete gnrh receptors thus gonadotrophin secretion, may beneficial certain clinical applications, reducing size fibroids, endometrial bleeding endometriosis . pelvic floor, abdominal chronic anal painbotulinum toxin type (pelvic floor) pelvic floor muscle over-activity plays role cppps. botulinum toxin type a, muscle relaxant, used reduce resting pressure pelvic floor muscles injection puborectalis pubococcygeus muscles used treat spasm levator ani pilot study twelve women pelvic floor muscle overactivity defined vaginal resting pressure > 40 cm h2o vaginal manometry reported reduction resting pressure improvement dyspareunia dysmenorrhoea, significant changes non-menstrual pelvic pain scores . sr including three rcts comparing btx-a saline injections pelvic floor found benefit pain scores six months follow-up despite reduction pelvic floor pressure . botulinum toxin type injected trigger points. expensive lidocaine proven effective . reviews support injection btx-a trigger points . botulinum toxin type also injected sphincter level improve urination defecation. relaxation urethral sphincter alleviates bladder problems secondarily spasm. cohort study thirteen patients cppps, btx-a injected external urethral sphincter. subjectively, eleven patients reported substantial change pain symptoms, score 7.2 1.6 vas . intermittent chronic primary anal pain syndrome due short duration episodes, medical treatment prevention often feasible. inhaled β-2 adrenergic agonist salbutamol effective rct patients frequent symptoms shortened pain duration . treatment options topic diltiazem btx-a . however, still controversy regarding duration pain intermittent chronic chronic primary anal pain syndrome. randomised controlled trials often use different definitions, extending pain duration (with shift chronic pain) order include patients better evaluate study-drug action. abdominal pain associated irritable bowel syndrome linaclotide, minimally absorbed peptide guanylate cyclase-c agonist dose 290 μg daily significantly improved abdominal pain (48.9% vs. 34.5% placebo-treated) bowel symptoms associated ibs constipation 26 weeks treatment . diarrhoea common adverse event patients treated linaclotide (4.5%). although known overlap ibs pelvic pain, effect latter assessed study. cochrane meta-analysis antispasmodics beneficial effect improvement abdominal pain compared placebo (58% improved antispasmodic compared 46% placebo) ibs . peppermint oil showed meta-analysis nine rct’s improvement abdominal pain patients ibs .